Business ❯ Healthcare ❯ Biotechnology

Pharmaceuticals

ImmunityBio, Inc. Vaccine Development Atara Biotherapeutics Cancer Treatment Cystic Fibrosis Treatments Clinical Trials Rare Diseases Monoclonal Antibodies Amgen Inc. Biologic Products Product Claims Cytokinetics Enzyme Replacement Therapy Immunotherapy Acquisitions Alzheimer's Treatments Neuroreparative Therapeutics Innovative Therapies Manufacturing Iovance Biotherapeutics Moderna ImmunityBio Axsome Therapeutics Immunology Cancer Therapies Asset Tokenization Cancer Therapy CAR T-cell Therapy Vaccines Gene Therapy Oncology Employment

Investors Vie to Lead ImmunityBio Securities Suit

An FDA warning about misleading Anktiva promotions has turned investor losses into the central issue in the fight over who will control the case.

NervGen Prices $60 Million Public Offering of Shares and Warrants

Boxer Capital Buys 1.24 Million Vir Biotechnology Shares

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over FDA Ad Rebuke

ImmunityBio Securities Fight Intensifies After FDA Rebuke Over Anktiva Claims

Axsome Reports 57% Q1 Sales Jump as FDA Clears Auvelity for Alzheimer’s Agitation

Class Action Filed Against Atara Biotherapeutics Over Alleged Misstatements on FDA Setbacks

ImmunityBio Investors Face May 26 Deadline in Class Action After FDA Flags Misleading Anktiva Claims

ImmunityBio Faces Investor Suits After FDA Rebuke as Anktiva Sales Jump

Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

ADMA Biologics Denies Short-Seller Report as Shares Rebound and Law Firms Launch Probes

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Kynam Trims Syndax Stake With $8.18 Million Q4 Sale Disclosed in SEC Filing

ClearBridge Growth Strategy Posts Third Straight Outperformance in Q4 2025

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform